BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

CHICAGO (Reuters) -The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

A new study published in the Journal of American Medical Association showed that the innovative small interfering RNA (siRNA) medication olpasiran (Amgen) can effectively reduce lipoprotein(a) ...

An ribonucleic acid (RNA) inhibitor, olpasiran (Amgen), which has shown it can lower lipoprotein(a) [Lp(a)] levels in patients with cardiovascular disease (CVD), has demonstrated in a phase 2 ...

Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China Background: Calcific aortic valve stenosis (CAVS) is a common cardiovascular ...